作者: Atul Batra , Rodrigo Rigo , Malek B. Hannouf , Winson Y. Cheung
DOI: 10.1016/J.CLCC.2020.09.006
关键词:
摘要: Abstract Background Use of fluoropyrimidine-based therapy in patients with metastatic colorectal cancer is associated significant toxicities. This study aimed to assess the safety and efficacy raltitrexed use who developed toxicities after treatment. Patients Methods We identified were treated raltitrexed-based systemic developing serious adverse events treatment a large Canadian province from 2004 2018. Demographic, tumor, characteristics retrieved electronic medical records. Progression-free overall survival assessed start therapy. Results A total 86 for study. The median age was 66.5 years, 58.1% men. primary site right, left, transverse colon 38.4%, 27.9%, 9.3%, respectively. remaining 24.4% had rectal cancer. Among all patients, 43.0% received more than 2 prior therapies, 37.6% previous cardiotoxicity progression-free 8.5 10.2 months, On multivariable Cox regression model, left-sided (hazard ratio [HR], 0.33; 95% confidence interval [CI], 0.12-0.97; P = .044) Eastern Cooperative Oncology Group performance status 0/1 (HR, 0.10; CI, 0.01-0.82; .032) longer survival, whereas left-sidedness only factor that predicted 0.30; 0.10-0.88; .029). Raltitrexed well-tolerated common included anemia 41.7% chemotherapy-induced nausea vomiting 27.4%. Most grade 1/2, but 16.7% experienced 3. There no cardiac treatment-related deaths. Conclusions previously effective well-tolerated.